Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms

Affiliations

¹ Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden (M.H., M.B.).
² Memorial Sloan-Kettering Cancer Center, New York, New York (O.L.).
³ University of Iceland and Landspitali National University Hospital, Reykjavik, Iceland (S.Y.K.).
⁴ Karolinska Institutet, Stockholm, Sweden (T.M.A.).

Comment

Malin Hultcrantz et al. Ann Intern Med. 2018.

. 2018 Aug 21;169(4):268.

doi: 10.7326/L18-0245.

¹ Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden (M.H., M.B.).
² Memorial Sloan-Kettering Cancer Center, New York, New York (O.L.).
³ University of Iceland and Landspitali National University Hospital, Reykjavik, Iceland (S.Y.K.).
⁴ Karolinska Institutet, Stockholm, Sweden (T.M.A.).

No abstract available

Comment on

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.
Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML. Hultcrantz M, et al. Ann Intern Med. 2018 Mar 6;168(5):317-325. doi: 10.7326/M17-0028. Epub 2018 Jan 16. Ann Intern Med. 2018. PMID: 29335713 Free PMC article.
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms.
Zhao JV, Schooling CM. Zhao JV, et al. Ann Intern Med. 2018 Aug 21;169(4):267-268. doi: 10.7326/L18-0244. Ann Intern Med. 2018. PMID: 30128517 No abstract available.